We are also excited by the NYP Second Opinion program through which patients anywhere in the U.S. are able to get a second opinion from a NewYork-Presbyterian physician in multiple disciplines including oncology, cardiology and orthopedics.
They have applied this approach to multiple aspects of oncology: monitoring patients who received cancer vaccines, investigating immunological mechanisms of antigen recognition in cancer, predicting therapeutic efficacy, and correlating immune complexity to patient outcomes.
These small RNA molecules bind the 3′UTR region of their messenger RNA (mRNA) targets, inducing posttranscriptional gene regulation by either inhibition of translation or mRNA degradation [ 2, 4, 5], and are being widely investigated with multiple approaches in oncology [ 6].
Invited experts represented multiple stakeholders, including urology, medical oncology, radiation oncology, industry, and patient advocates.
Dogs have been used as predictive models for human oncology in multiple cancers [ 8], including lymphoma [ 9, 10].
Biomarkers are involved in multiple phases of medical oncology, including prediction, diagnosis, prognosis, monitoring treatment response, and recurrence.
ALL was chosen as it has one of the most refined risk determination classifications in pediatric oncology, incorporating multiple biologic factors [ 10].
Hodge et al. simultaneously determined multiple cytokines in childhood oncology patients with febrile neutropenia and found increased IL-8 or IL-5 correlating with culture-positive infection [ 21].
Based on this selection process, the following groups were taken into consideration: cardiovascular medicines, contrast media, hematology medicines, neurology medicines (especially for Multiple Sclerosis), nutrition (electrolyte), oncology medicines (breast, colon, leukemia), and transfusion medicines.
KMB has received consultancy fees from Celgene Corporation, AstraZeneca, Worldwide Clinical Trials, Integrium LLC, Cypress Pharmaceuticals, Sigma-Tau PhaResearchcals, Outcomes Research (now owned by Quintiles), Multiple Myeloma Research Foundation, MedImmune, ACT Oncology and BioSoteria.
